Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | YAP1 | P46937 | 2/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876978 | 0.92 | KDM4E (0.56) | KDM4EPKMGPR119STSYAP1 | |
| SCHEMBL26668458 | 0.91 | SLC2A1 (0.59) | KDM4EPKMGPR119CSF1RCHEK2 | |
| SCHEMBL12813454 | 0.91 | YAP1 (0.66) | KDM4EPKMGPR119STSYAP1 | |
| SCHEMBL65285 | 0.89 | GPR119 (0.59) | KDM4EPKMGPR119CHEK2SLC2A1 | |
| SCHEMBL12834985 | 0.88 | GPR119 (0.58) | KDM4EPKMGPR119CSF1RCHEK2 | |
| SCHEMBL2158159 | 0.88 | GPR119 (0.65) | KDM4EPKMGPR119STSCSF1R | |
| SCHEMBL15412759 | 0.88 | GPR119 (0.58) | KDM4EPKMGPR119CHEK2 | |
| SCHEMBL13097087 | 0.88 | SLC2A1 (0.57) | KDM4EPKMGPR119CSF1RCHEK2 | |
| SCHEMBL13096956 | 0.88 | YAP1 (0.60) | KDM4EPKMGPR119STSCSF1R | |
| SCHEMBL6406782 | 0.87 | SLC2A1 (0.58) | GPR119CHEK2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| WO-2020154571-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20170121349-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2017-05-04 | — | — | US | disclosed |
| EP-1467995-B1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645754-B2 | Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261943-A1 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | NR0B2, NR0B1, ADORA2B | KDM4E 3370/4885PKM 4003/4885GPR119 263/4885 |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, OXER1, CNR1 | KDM4E 4046/4885PKM 4410/4885GPR119 328/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | KDM4E 1073/4885PKM 833/4885GPR119 3998/4885 |
| US-20170121349-A1 | Anti-Infective Compounds | FNTB, LSS, PGLS | KDM4E 3797/4885PKM 2368/4885GPR119 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.